vProtect™ luminal shield system

Long‐term impact of balloon postdilatation on neointimal formation: An experimental comparative study between second‐generation self‐expanding versus balloon‐expandable stent technologies

“…A new generation of SES is under development that aims to treat complex atherosclerotic lesions (i.e., acute myocardial infarction) []. These devices intend to improve clinical outcomes by providing suitable outward forces to attain proper vessel wall apposition, controlled luminal gain, and reduced vessel injury.…”

“…However, due to their intrinsic mechanical properties SES are still believed to potentially be able to induce less injury at the time of implantation and better device apposition as the vessel remodels . Second‐generation coronary SES are under development as potential alternatives for the treatment of coronary artery disease []. Because of the different biomechanical properties displayed by these technologies, it is expected that the patterns of vascular injury and healing will differ.…”

First case of stenting of a vulnerable plaque in the SECRITT I trial—the dawn of a new era?

“…21 Animal studies, involving rabbit iliac artery injury models, demonstrated that the vProtect ® Luminal Shield can promote vascular healing to achieve complete endothelialization of the stented vessel segment in 7 days. 3 Although atherosclerosis is a systemic disease, and aggressive management of cardiac risk factors is warranted, 22,23 many patients are on appropriate medical therapy, including statins and antihypertensives, when they present with an acute coronary syndrome. Mechanical modification of the plaque might be considered crude, but stent technology has radically changed over the years.…”

“…1 The SECRITT I (Santorini Criteria 2 for Investigating and Treating Thin Capped Fibroatheroma) trial ( Figure 1) required treatment of the culprit lesions with a drugeluting stent, followed by treatment of the IDTCFA with a self-expanding stent tailored to treat vulnerable plaques-the vProtect ® Luminal Shield (Prescient Medical, Inc., Doylestown, PA). 3 The culprit lesion in the left circumflex coronary artery was crossed with a magnetically enabled Titan ™ The patient was observed overnight and discharged home following a normal cardiac biochemical profile (creatine kinase = 125 ng/ml, creatine kinase-MB isoenzyme = 0.5 ng/ml and troponins <0.05 ng/ml). Medications on discharge were metformin 1 g twice daily, and aspirin 75 mg, atorvastatin 40 mg and felodipine 5 mg, once daily.…”

Future Directions of Drug‐Eluting Stents

“…These devices may require different mechanical properties and alternative drugs from the routine third‐generation DES. The vProtect™ shield (Prescient Medical, Doylestown, PA) is such a device: 67 this thin strut self‐expanding nitinol stent is currently being evaluated for this purpose, although it is important to realize that the long‐term event rates with this bare metal device are currently unknown.…”